Rok Cerne

respirerx pharmaceuticals inc

H指数:16

被引数:932

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Low-Impact Ampakine CX717 Exhibits Promising Therapeutic Profile in Adults with ADHD – A Phase 2A Clinical Trial

低影响Ampakine CX717在成人ADHD患者中表现出有希望的疗效特征——一项2A期临床试验

European Journal of Pharmacology

IF4.7

2025-08-070

PRE

Antipsychotic-like pharmacological profile of the low impact ampakine CX691 (farampator): Implications for the use of low impact ampakines in the treatment of schizophrenia

低影响AMPA受体激动剂CX691（farampator）的抗精神病样药理学特征：对低影响AMPA受体激动剂在精神分裂症治疗中应用的启示

JOURNAL OF PSYCHIATRIC RESEARCH

IF3.2

2025-06-010

PRE

Safety, tolerability and pharmacokinetic profile of the low-impact ampakine CX717 in young healthy male subjects and elderly healthy male and female subjects

EUROPEAN JOURNAL OF PHARMACOLOGY

IF4.7

2025-04-010

PRE

Nonsedating anxiolytics

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

IF2.5

2024-12-010

PRE

Traumatic brain injury: molecular biomarkers, genetics, secondary consequences, and medical management

FRONTIERS IN NEUROSCIENCE

IF3.2

2024-10-040

OAAI

Preclinical characterization of a water-soluble low-impact ampakine prodrug, CX1942 and its active moiety, CX1763

FUTURE MEDICINAL CHEMISTRY

IF3.4

2024-09-201

PRE

Is there a biochemical basis for purinergic P2X3 and P2X4 receptor antagonists to be considered as anti-seizure medications?

BIOCHEMICAL PHARMACOLOGY

IF5.6

2024-04-011

PRE

Mechanistic and therapeutic relationships of traumatic brain injury and γ-amino-butyric acid (GABA)

创伤性脑损伤与 γ-氨基丁酸 (GABA) 的机理和治疗关系

PHARMACOLOGY & THERAPEUTICS

IF12.5

2024-04-013

PRE

Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents

FUTURE PHARMACOLOGY

IF2.7

2024-02-264

New Imidazodiazepine Analogue, 5-(8-Bromo-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole, Provides a Simplified Synthetic Scheme, High Oral Plasma and Brain Exposures, and Produces Antiseizure Efficacy in Mice, and Antiepileptogenic Activity in Neural Networks in Brain Slices from a Patient with Mesial Temporal Lobe Epilepsy

ACS CHEMICAL NEUROSCIENCE

IF3.9

2024-01-042

PRE

KRM-II-81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy

HELIYON

IF3.6

2024-01-012

OAAI

Structural Analogs of the GABAkine KRM-II-81 Are Orally Bioavailable Anticonvulsants without Sedation

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2023-04-017

OAAI

Comparative anticonvulsant activity of the GABAkine KRM-II-81 and a deuterated analog

GABAkine KRM-II-81和氘代类似物的抗惊厥活性比较

DRUG DEVELOPMENT RESEARCH

IF4.2

2023-02-072

Hydrochloride Salt of the GABAkine KRM-II-81

ACS OMEGA

IF4.3

2022-07-2711

OAAI

Can GABAkines quiet the noise The GABAA receptor neurobiology and pharmacology of tinnitus

BIOCHEMICAL PHARMACOLOGY

IF5.6

2022-07-014

PRE

GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors

PHARMACOLOGY & THERAPEUTICS

IF12.5

2022-06-0166

OAAI

N-Substituted-3-alkoxy-derivatives of dextromethorphan are functional NMDA receptor antagonists in vivo: Evidence from an NMDA-induced seizure model in rats

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

IF2.5

2021-04-015

OAAI

The α2,3-selective potentiators of GABAA receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

IF2.5

2020-09-0118

OAAI

Imidazodiazepine Anticonvulsant, KRM-II-81, Produces Novel, Non-diazepam-like Antiseizure Effects

ACS CHEMICAL NEUROSCIENCE

IF3.9

2020-07-3019

OAAI

The Positive Allosteric Modulator of α2/3-Containing GABAA Receptors, KRM-II-81, Is Active in Pharmaco-Resistant Models of Epilepsy and Reduces Hyperexcitability after Traumatic Brain Injury

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2020-01-0130

OAAI

Rok Cerne

个人简介

教育背景

工作经历

荣誉奖项

研究方向